Products
Newsletter
Recombinant proteins and receptors - highly pure and active recombinant proteins expressed in HEK293 cells.
The efficacy of a therapeutic antibody not only depends on the Fab fragment and its binding activity to the target antigen, but also depends on the Fc fragment and its interaction with key Fc receptors. The binding affinity of the Fc fragment towards FcRn (FCGRT&B2M) would predict the antibody’s half life, while that between the Fc fragment and FCGRIIIA (CD16a) would influence the antibody’s ability to elicit ADCC (antibody dependent cell mediated cytotoxicity). Hence, screening for desired binding affinity to these Fc receptors is an essential component in the development of a therapeutic mAb (monoclonal antibody).
We offer a comprehensive collection of recombinant Fc receptor proteins of different species (human, mouse, rat, cynomolgus, porcine) including their common variants.
The single domain antibody was originally discovered in camels back in 1993. This new class of antibody is heavy chain only, containing a single variable domain (VHH) and two constant domains (CH2, CH3). This rare form of antibody has following unique advantages, which makes it an intriguing alternative to the conventional antibodies when it comes to therapeutic use.
First, because of its small size, these nanobodies are known to be able to reach to the cryptic epitopes of the targets normally not accessible by the much larger traditional antibodies. The stability of these antibodies is much better than the traditional antibodies, which makes it possible to be delivered through oral and maybe ocular routes, in addition to intravenous and subcutaneous injection. The nanobodies can also be easily conjugated with cell-killing agents if needed. Last but not least, from manufacturing standpoint, nanobodies are much easier to produce from a variety of hosts.
ACROBiosystems provides a unique portfolio of llama lgG Fc tagged recombinant antigens, which are uniquely designed for llama immunization.
ACROBiosystems has been keeping a close eye on the development of the epidemic situation and accelerating the development of SARS-COV-2 antigen proteins, antibodies, kits and other related products to facilitate the development of serologic tests, therapeutic antibodies and vaccines. ACROBiosystems has developed over 100 products related to SARS-CoV-2, including recombinant proteins, antibodies, kits, beads and so on covering the critical targets of SARS-CoV-2.
To support the research on the monkeypox virus, ACROBiosystems has successfully developed the MPXV E8L and A30L antigens, which are now in stock! In addition, A35R, A29L, B21R and other core research tools for MPXV are coming soon!
Follow us